BB
The startup develops small molecules to treat sensory hyperexcitability disorders by targeting both a ligand-gated cation channel and a voltage-gated potassium channel. This dual-target approach enhances therapeutic efficacy and safety for patients experiencing heightened sensory responses.
Updated 3 months ago
Funding
$18M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops small molecules to treat sensory hyperexcitability disorders by targeting both a ligand-gated cation channel and a voltage-gated potassium channel. This dual-target approach enhances therapeutic efficacy and safety for patients experiencing heightened sensory responses.